Navigation Links
Perrigo Receives FDA Approval to Market Coated Fruit Nicotine Gum

The Perrigo Company today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market over-the-counter coated nicotine polacrilex gum USP, 2 mg (coated fruit) and 4 mg (coated fruit).

The product will be marketed under store brand labels and is comparable to GlaxoSmithKline's Nicorette(R) Fruit Chill(TM) coated gum, which is an aid to smoking cessation. "This first store brand approval of coated fruit nicotine gum extends our leading store brand position.

The expanded range of smoking cessation products also includes coated mint-flavored gum, uncoated gum and lozenges," said Joseph C. Papa, Perrigo's President and Chief Executive Officer. Nicorette(R) Fruit Chill(TM) gum is selling at an annual rate estimated at over $70 million at all retail outlets. First shipments are expected within the first quarter of fiscal 2008.

The Perrigo Company is a leading global healthcare supplier and the world's largest manufacturer of over-the-counter (OTC) pharmaceutical and nutritional products for the store brand market. Store brand products are sold by food, drug, mass merchandise, dollar store and club store retailers under their own labels. The Company also develops, manufactures and markets prescription generic drugs, active pharmaceutical ingredients and consumer products, and operates manufacturing facilities in the United States, Israel, United Kingdom, Mexico, Germany and China.

Note: Certain statements in this press release are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially di
'"/>




Page: 1 2

Related medicine news :

1. Fifth US Patient Receives Artificial Heart
2. Northfield Labs Receives FDA Comments
3. British MPs Say Prostate Cancer Receives Low Priority in the NHS
4. Abbott Receives CE Mark Certification
5. Zactima Receives Fast Track Designation By The FDA
6. East London Receives World Class New Private Hospital Facility
7. Brinda Karat Receives Legal Notice over Ramdev Issue
8. Quake-Hit Pakistan Receives 30 Field Hospitals From Cuba
9. Medtronic’s Insulin Pump Receives Regulatory Approva
10. Aurobindo Receives Approval from USFDA for anti-AIDS drug
11. Sunscreen Blocking UVA Radiation Receives Federal Approval
Post Your Comments:
(Date:5/15/2008)...-869 to be Promising in Targeting Cancer Cells, ...TT PARK, Ill., May 15 /PRNewswire-FirstCall/ -- Ab... trial data of several investigative,compounds in ...rican,Society of Clinical Oncology (ASCO) Annual M...ntations include ABT-263, a Bcl-2 family protein,a...
(Date:5/15/2008)...inhua-PRNewswire-FirstCall/ -- China Yingxia,Inter...Yingxia" or "the,Company"), a leading provider in ...ent, manufacture and distribution of organic nutri...re products in the People,s Republic,of China ("PR...first,quarter ended March 31, 2008., First Quar...
(Date:5/15/2008)... goal of tailoring cancer treatment for each indiv...l Center today presented a study suggesting a simp...s treatment efficacy for patients with metastatic ...ometimes months to determine if a particular cance...ng to observe any significant radiographic changes...
(Date:5/15/2008)...n called IGF-1R in patients with gastrointestinal ...ient would be less responsive to the drug imatinib...K. Godwin, Ph.D., a researcher at the Fox Chase Ca...have shown that GIST cells, especially Gleevec-res...lopment for treatment-resistant breast cancer, a f...
Breaking Medicine News(10 mins):Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 2Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 3Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 4Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 5Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 6Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 2Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 3Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 4Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 5Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 6Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 7Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 8Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 9Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:Protein predicts Gleevec resistance in gastrointestinal tumors 2
...ranean diet is a simple recipe for good health. Ha...0 Greeks found that those consuming the classic di...and vegetables and accompanied by a moderate amoun...id not."The closer you are to adhering to this die...
...mething, let it out and it might save you a headac...alize their anger more than those without headache..., 171 suffered from headaches. Investigators measu...perienced in daily life), internalized anger, host...
...bilt University shows cholesterol-lowering effects...ea. The study is the first placebo-controlled clin...perties of tea in humans. Studies of large populat...h benefits that include lower levels of LDL, or ba...
...occasional "bad day" are at increased risk of deve...w study . It is not uncommon for people over age 7...g in bed for at least half a day and/or cutting ba...e past month. Most physicians believe this is just...
Other Medicine News:Health News:Eat Like a Greek for Good Health 2
(Date:5/15/2008)...trated in Blacks, Hispanics/Latinos, People ...ARSIPPANY, N.J., May 15 /- Daiichi Sa... the American Society of,Hypertension,s Twenty- Th...leans demonstrated that the powerful combination d... safely and effectively helped,patients across sev...
(Date:5/15/2008)...15 /- Ergonex Pharma today,announced ...n (FDA) has,granted orphan drug designation to Ter...ertension (PAH). Terguride is currently being eval...e., "The FDA,s grant of orphan drug designation t... development program by offering regulatory,clini...
(Date:5/15/2008)... for an Antiplatelet Therapy that, Combined, with ... of Plavix/Iscover and Aspirin, According to a...s., May 15 /- Decision Resources, one...s for pharmaceutical and,healthcare issues, finds ...rovement in patient compared to Sanofi-Aventis/Bri...
(Date:5/15/2008)...Annual Meeting of The American Society of ..., IRVINE, Calif., May 15 /...today announced the presentation of updated data,f...murtide (L-MTP-PE) in,patients with lung metastase...a rare and often fatal bone tumor that typically a...
Breaking Medicine Technology:Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 2IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 3IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 4IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 5IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 6Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution 1599 1Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution 1599 2Personalized Medicine The Genomic Revolution in Cardiac Care 330 1Personalized Medicine The Genomic Revolution in Cardiac Care 330 2Personalized Medicine The Genomic Revolution in Cardiac Care 330 3Alba Therapeutics Announces Phase IIb Clinical Trial for Oral AT 1001 for the Treatment of Celiac Disease 326 1Alba Therapeutics Announces Phase IIb Clinical Trial for Oral AT 1001 for the Treatment of Celiac Disease 326 2Early Human Like Skeletons Are First Outside of Africa 1595 1Early Human Like Skeletons Are First Outside of Africa 1595 2Early Human Like Skeletons Are First Outside of Africa 1595 3
...tection Observed Prior to or Up to 24 Hours After,...7 /PRNewswire/ -- Targanta,Therapeutics Corporatio...demonstrating oritavancin as a potential therapy f...cterium which causes anthrax,an acute infectious ...glycopeptide antibiotic for the treatment of serio...
...-(BUSINESS WIRE)--May 25, 2007 - GTx, Inc., (NASDA... Phase II proof of,concept clinical trial of Ostar...ial evaluating ACAPODENE(R) (toremifene citrate) 8... androgen,deprivation therapy (ADT) will be presen...rican Society of Clinical Oncology being,held June...
Other Medicine Technology:Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax 2Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax 3Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax 4GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 2GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 3
A Western Blot Immunassay for the detection of antibodies to primarily anti-myelin associated glycoproteins (anti-MAG) and other glycolipid autoantibodies in human serum.
Triturus® is an open and completely automated ELISA immunoassay analyzer which can perform a variety of different tests on a series of samples and process several batches simultaneously.
...nesthesia and Respiratory Products, ,Westmed desi...ical devices for Anesthesia and Respiratory profes...products that enhance the clinician's ability to d...ention to the bottom line. , ,Our web site is des...
...he age of 3 can choose either the PARI LC PLUS®...applies to both:, ,Maximize aerosol output when t...n the patient exhales using two one-way valves. Ba... nebulizer. The result is a high percentage of par...
Medicine Products: